{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Dedifferentiated+Carcinoma",
    "query": {
      "condition": "Endometrial Dedifferentiated Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T14:46:32.913Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05256225",
      "title": "Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Carcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Dedifferentiated Carcinoma",
        "Endometrial Endometrioid Adenocarcinoma",
        "Endometrial Mixed Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "High-Dose-Rate Vaginal Cuff Brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "Hyaluronidase-zzxf/Pertuzumab/Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Trastuzumab/Hyaluronidase-oysk",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 360,
      "start_date": "2022-11-16",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-06-25T14:46:32.913Z",
      "location_count": 403,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 304 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05256225"
    },
    {
      "nct_id": "NCT05112601",
      "title": "Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Dedifferentiated Carcinoma",
        "Endometrial Endometrioid Adenocarcinoma",
        "Endometrial Mixed Cell Adenocarcinoma",
        "Endometrial Mucinous Adenocarcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Recurrent Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 81,
      "start_date": "2022-06-02",
      "completion_date": "2032-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-06-25T14:46:32.913Z",
      "location_count": 137,
      "location_summary": "Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05112601"
    },
    {
      "nct_id": "NCT05049538",
      "title": "Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Dedifferentiated Carcinoma",
        "Endometrial Mucinous Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Malignant Uterine Neoplasm",
        "Uterine Corpus Carcinosarcoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Liquid Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Pap Smear",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2019-06-18",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-06-25T14:46:32.913Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05049538"
    },
    {
      "nct_id": "NCT03914612",
      "title": "Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Dedifferentiated Carcinoma",
        "Endometrial Endometrioid Adenocarcinoma",
        "Endometrial Mixed Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Recurrent Endometrial Adenocarcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Endometrial Clear Cell Adenocarcinoma",
        "Recurrent Endometrial Dedifferentiated Carcinoma",
        "Recurrent Endometrial Endometrioid Adenocarcinoma",
        "Recurrent Endometrial Mixed Cell Adenocarcinoma",
        "Recurrent Endometrial Serous Adenocarcinoma",
        "Recurrent Endometrial Undifferentiated Carcinoma",
        "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 813,
      "start_date": "2019-08-22",
      "completion_date": "2026-09-26",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-06-25T14:46:32.913Z",
      "location_count": 370,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03914612"
    }
  ]
}